Natco Pharma arm launches first generic alternative to Revlimid in Canada

Sales of oncology medicines have nearly tripled over the past decade with a shift towards higher-cost drugs. Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells and the second most common form of blood cancer. Patients with this type of cancer may have low blood cell counts and immune problems giving them a higher chance for getting infections such as pneumonia. The bones can be affected leading to bone pain and breaks (fractures). About 7,400 Canadians are living with or are in remission from myeloma and every day, 9 Canadians are diagnosed with the disease. To date there is no cure for myeloma, however several types of treatments help control the disease.

"As self-administered capsules, lenalidomide is an important therapy for Canadian patients whose lives are critically impacted by a variety of myeloma-related events and symptoms. This treatment aims at prolonging survival and improving quality of life. The availability of NAT-LENALIDOMIDE as the first generic alternative to Revlimid is excellent news," commented Joe Kamel, Registered Pharmacist, at PureHealth Pharmacy in Barrie, Ontario.

PrNat-Lenalidomide is available through the RevAid risk management plan in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules.

Also Read:Natco Pharma Lenalidomide Capsules secures USFDA okay